{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:43:26Z","timestamp":1790912606589,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>The expanding and dynamic market of new psychoactive substances (NPSs) poses challenges for laboratories worldwide. The retrospective data analysis (RDA) of previously analyzed samples for new targets can be used to investigate analytes missed in the first data analysis. However, RDA has historically been unsuitable for routine evaluation because reprocessing and reevaluating large numbers of forensic samples are highly work- and time-consuming. In this project, we developed an efficient and scalable retrospective data analysis workflow that can easily be tailored and optimized for groups of NPSs. The objectives of the study were to establish a retrospective data analysis workflow for benzodiazepines in whole blood samples and apply it on previously analyzed driving-under-the-influence-of-drugs (DUID) cases. The RDA workflow was based on a training set of hits in ultrahigh-performance liquid chromatography\u2013quadrupole time-of-flight\u2013mass spectrometry (UHPLC-QTOF-MS) data files, corresponding to common benzodiazepines that also had been analyzed with a complementary UHPLC\u2013tandem mass spectrometry (MS\/MS) method. Quantitative results in the training set were used as the true condition to evaluate whether a hit in the UHPLC-QTOF-MS data file was true or false positive. The training set was used to evaluate and set filters. The RDA was used to extract information from 47 DBZDs in 13,514 UHPLC-QTOF-MS data files from DUID cases analyzed from 2014 to 2020, with filters on the retention time window, count level, and mass error. Sixteen designer and uncommon benzodiazepines (DBZDs) were detected, where 47 identifications had been confirmed by using complementary methods when the case was open (confirmed positive finding), and 43 targets were not reported when the case was open (tentative positive finding). The most common tentative and confirmed findings were etizolam (<jats:italic>n<\/jats:italic> = 26), phenazepam (<jats:italic>n<\/jats:italic> = 13), lorazepam (<jats:italic>n<\/jats:italic> = 9), and flualprazolam (<jats:italic>n<\/jats:italic> = 8). This method efficiently found DBZDs in previously acquired UHPLC-QTOF-MS data files, with only nine false-positive hits. When the standard of an emerging DBZD becomes available, all previously acquired DUID data files can be screened in less than 1\u00a0min. Being able to perform a fast and accurate retrospective data analysis across previously acquired data files is a major technological advancement in monitoring NPS abuse.<\/jats:p>","DOI":"10.3389\/fchem.2022.868532","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:18:46Z","timestamp":1652941126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A New Strategy for Efficient Retrospective Data Analyses for Designer Benzodiazepines in Large LC-HRMS Datasets"],"prefix":"10.3389","volume":"10","author":[{"given":"Meiru","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Schou","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petur Weihe","family":"Dalsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Brinch","family":"Mollerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Katrine Klose","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Linnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/15563650.2018.1506130","article-title":"Occurrence and Time Course of NPS Benzodiazepines in Sweden - Results from Intoxication Cases in the STRIDA Project","volume":"57","author":"B\u00e4ckberg","year":"2019","journal-title":"Clin. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113569","DOI":"10.1016\/j.jpba.2020.113569","article-title":"Rapid and Simple Multi-Analyte LC-MS\/MS Method for the Determination of Benzodiazepines and Z-Hypnotic Drugs in Blood Samples: Development, Validation and Application Based on Three Years of Toxicological Analyses","volume":"191","author":"Banaszkiewicz","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.forsciint.2018.08.032","article-title":"Proactive Drugs in DFSA Cases: Toxicological Findings in an Eight-Years Study","volume":"291","author":"Bertol","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0242224","DOI":"10.1371\/journal.pone.0242224","article-title":"How to Perform Spectrum-Based LC-HR-MS Screening for More Than 1,000 NPS with HighResNPS Consensus Fragment Ions","volume":"15","author":"Davidsen","year":"2020","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","article-title":"New Psychoactive Substances: Global Markets, Global Threats and the COVID-19 pandemic\u2014an Update From the EU Early Warning System","year":"2020","DOI":"10.2810\/921262"},{"key":"B6","doi-asserted-by":"publisher","article-title":"European Drug Report 2021: Trends and Developments","year":"","DOI":"10.1093\/tandt\/3.1.3"},{"key":"B7","doi-asserted-by":"publisher","article-title":"New Benzodiazepines in Europe \u2013 a Review","year":"","DOI":"10.2810\/725973"},{"key":"B8","article-title":"The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/dta.2897","article-title":"Retrospective Analysis of New Psychoactive Substances in Blood Samples of German Drivers Suspected of Driving under the Influence of Drugs","volume":"12","author":"Fels","year":"2020","journal-title":"Drug Test. Anal."},{"key":"B10","doi-asserted-by":"publisher","first-page":"110274","DOI":"10.1016\/j.forsciint.2020.110274","article-title":"Retrospective Screening of Synthetic Cannabinoids, Synthetic Opioids and Designer Benzodiazepines in Data Files from Forensic post Mortem Samples Analysed by UHPLC-QTOF-MS from 2014 to 2018","volume":"311","author":"Gundersen","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jps.2600790916","article-title":"Liquid Chromatographic Assay and Pharmacokinetics of Halatepam and its Metabolite in Humans","volume":"79","author":"Gupta","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"110901","DOI":"10.1016\/J.FORSCIINT.2021.110901","article-title":"Simple Implementation of Muscle Tissue into Routine Workflow of Blood Analysis in Forensic Cases - A Validated Method for Quantification of 29 Drugs in Postmortem Blood and Muscle Samples by UHPLC-MS\/MS","volume":"325","author":"Hansen","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0379-0738(00)00226-7","article-title":"Screening and Determination of Benzodiazepines in Whole Blood Using Solid-phase Extraction and Gas Chromatography\/mass Spectrometry","volume":"113","author":"Inoue","year":"2000","journal-title":"Forensic Sci. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/jat\/bkz030","article-title":"HighResNPS.com: An Online Crowd-Sourced HR-MS Database for Suspect and Non-targeted Screening of New Psychoactive Substances","volume":"43","author":"Mardal","year":"2019","journal-title":"J. Anal. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/dta.2120","article-title":"Targeted and Non-targeted Drug Screening in Whole Blood by UHPLC-TOF-MS with Data-independent Acquisition","volume":"9","author":"Mollerup","year":"2017","journal-title":"Drug Test. Anal."},{"key":"B16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/dta.2543","article-title":"Retrospective Analysis for Valproate Screening Targets with Liquid Chromatography-High Resolution Mass Spectrometry with Positive Electrospray Ionization: An Omics\u2010based Approach","volume":"11","author":"Mollerup","year":"2019","journal-title":"Drug Test. Anal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/dta.2263","article-title":"Application of a Screening Method for Fentanyl and its Analogues Using UHPLC-QTOF-MS with Data-independent Acquisition (DIA) in MSE Mode and Retrospective Analysis of Authentic Forensic Blood Samples","volume":"10","author":"Noble","year":"2018","journal-title":"Drug Test. Anal."},{"key":"B18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2174\/1570159x18666200110121333","article-title":"'New\/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports","volume":"18","author":"Orsolini","year":"2020","journal-title":"Cn"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.forsciint.2019.02.039","article-title":"A Retrospective Analysis of Data from Forensic Toxicology at the Academy of Forensic Science in 2017","volume":"298","author":"Pan","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/jat\/bky039","article-title":"A Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data","volume":"42","author":"Partridge","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of Designer Benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II Immunochemical Screening Assays","volume":"9","author":"Pettersson Bergstrand","year":"2016","journal-title":"Drug Test. Anal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"111207","DOI":"10.1016\/J.FORSCIINT.2022.111207","article-title":"The Incidence of Psychoactive Substances and Alcohol Among Impaired Drivers in Denmark in 2015-2019","volume":"333","author":"Simonsen","year":"2022","journal-title":"Forensic Sci. Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/15389581003792783","article-title":"The Frequency of Drugs Among Danish Drivers before and after the Introduction of Fixed Concentration Limits","volume":"11","author":"Steentoft","year":"2010","journal-title":"Traffic Inj. Prev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.forsciint.2017.09.010","article-title":"Toxicological Findings in Suspected Drug-Impaired Drivers in Norway - Trends during 1990-2015","volume":"280","author":"Valen","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An Expanding World of New Psychoactive Substances-Designer Benzodiazepines","volume":"73","author":"Zawilska","year":"2019","journal-title":"Neurotoxicology"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2022.868532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T09:55:18Z","timestamp":1653472518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2022.868532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":25,"alternative-id":["10.3389\/fchem.2022.868532"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2022.868532","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"868532"}}